Epidemiology of COVID‐19: A systematic review and meta‐analysis of clinical characteristics, risk factors, and outcomes
Jie Li,Daniel Q. Huang,Biyao Zou,Hongli Yang,Wan Zi Hui,Fajuan Rui,Natasha Tang Sook Yee,Chuanli Liu,Sanjna Nilesh Nerurkar,Justin Chua Ying Kai,Margaret Li Peng Teng,Xiaohe Li,Hua Zeng,John A. Borghi,Linda Henry,Ramsey Cheung,Mindie H. Nguyen
DOI: https://doi.org/10.1002/jmv.26424
IF: 20.693
2020-08-25
Journal of Medical Virology
Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>COVID‐19 has become a pandemic, but its reported characteristics and outcomes vary greatly amongst studies.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Objectives</h3><p>We determined pooled estimates for clinical characteristics and outcomes in COVID‐19 patients including subgroups by disease severity (based on WHO Interim Guidance Report or IDSA/ATS criteria) and by country/region.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>We searched Pubmed, Embase, Scopus, Cochrane, Chinese Medical Journal, and preprint databases from January 1, 2020 to April 6, 2020. Studies of laboratory confirmed COVID‐19 patients with relevant data were included. Two reviewers independently performed study selection and data extraction.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>From 6,007 articles, 212 studies from 11 countries/regions involving 281,461 individuals were analyzed. Overall, mean age was 467 years, 51.8% were male, 22.9% had severe disease, and mortality was 5.6%. Underlying immunosuppression, diabetes, and malignancy were most strongly associated with severe COVID‐19 (coefficient=53.9, 23.4, 23.4, respectively, all p<0.0007), while older age, male gender, diabetes, and hypertension were also associated with higher mortality (coefficient=0.05 per year, 5.1, 8.2, 6.99, respectively, p=0.006 to 0.0002). Gastrointestinal (nausea, vomiting, abdominal pain) and respiratory symptoms (shortness of breath, chest pain) were associated with severe COVID‐19, while pneumonia and end organ failure were associated with mortality. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>COVID‐19 is associated with a severe disease course in about 23% and mortality in about 6% of infected persons. Individuals with comorbidities and clinical features associated with severity should be monitored closely, and preventive efforts should especially target those with diabetes, malignancy and immunosuppression.</p><p>This article is protected by copyright. All rights reserved.</p></section>
virology